Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Aktien Schweiz Eröffnung: Nahostkrieg sorgt für Verluste auf breiter Front (Cash) +++ NESTLE Aktie +4,36%

BAVARIAN NORDIC Aktie

 >BAVARIAN NORDIC Aktienkurs 
25.75 EUR    -2.2%    (TradegateBSX)
Ask: 25.83 EUR / 390 Stück
Bid: 25.75 EUR / 390 Stück
Tagesumsatz: 1316 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>BAVARIAN NORDIC Performance
1 Woche: +0,2%
1 Monat: -0,4%
3 Monate: +6,9%
6 Monate: -15,6%
1 Jahr: +15,7%
laufendes Jahr: +2,9%
>BAVARIAN NORDIC Aktie
Name:  BAVARIAN NORDIC
Land:  Dänemark
Sektor:  Gesundheit
ISIN/ Wkn:  DK0015998017 / 917165
Symbol/ Ticker:  BV3 (Frankfurt)
Kürzel:  FRA:BV3, ETR:BV3, BV3:GR
Index:  -
Webseite:  https://www.bavarian-nord..
Profil:  Bavarian Nordic A/S is a Danish biotechnology company specializing in the research, development, manufacturing, and commercialization of innovative vaccines based on viral vector technologies. Headqua..
>Volltext..
Marktkapitalisierung:  2083.44 Mio. EUR
Unternehmenswert:  1704.05 Mio. EUR
Umsatz:  909.85 Mio. EUR
EBITDA:  312.76 Mio. EUR
Nettogewinn:  324.5 Mio. EUR
Gewinn je Aktie:  4.15 EUR
Schulden:  17.79 Mio. EUR
Liquide Mittel:  277.78 Mio. EUR
Operativer Cashflow:  415.72 Mio. EUR
Bargeldquote:  1.66
Umsatzwachstum:  12.47%
Gewinnwachstum:  117.92%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  BAVARIAN NORDIC
Letzte Datenerhebung:  02.03.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 78.27 Mio. St.
Frei handelbar: 88.51%
Leerverk. Aktien: -
Rückkaufquote: 0.43%
Mitarbeiter: 1611
Umsatz/Mitarb.: 0.42 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 37.15%
Bewertung:
KGV: 6.23
KGV lG: 9.01
KUV: 2.23
KBV: 1.16
PEG-Ratio: 0.05
EV/EBITDA: 5.45
Rentabilität:
Bruttomarge: 54.11%
Gewinnmarge: 35.67%
Operative Marge: 24.1%
Managementeffizenz:
Gesamtkaprendite: 16.8%
Eigenkaprendite: 20.51%
>Peer Group
Gesundheit, Impfstoffentwicklung/ Impfstoffhersteller
 
02.03.26 - 09:12
Bavarian Nordic CEO Steps Down After Failed $3 Billion Deal (Bloomberg)
 
Bavarian Nordic A/S's Chief Executive officer Paul Chaplin will step down, marking the second major leadership shake-up at the vaccine maker since shareholders torpedoed a takeover bid last year....
02.03.26 - 08:09
Bavarian Nordic CEO Paul Chaplin to step down after 27 years (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.03.26 - 07:45
Paul Chaplin Steps Down as CEO of Bavarian Nordic (GlobeNewswire EN)
 
COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The Board of Directors has initiated the process to identify a new CEO....
18.02.26 - 08:03
Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada (GlobeNewswire EN)
 
COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company's mpox and smallpox vaccine, MVA-BN®....
12.02.26 - 10:36
Bavarian Nordic shares rise as Q4 revenue beats on travel vaccine demand (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
12.02.26 - 07:45
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026 (GlobeNewswire EN)
 
Bavarian Nordic announces preliminary, unaudited financial results for 2025 and provides financial guidance for 2026....
09.02.26 - 09:24
Bavarian Nordic – Completion of Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 500 million in 2026. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure....
02.02.26 - 08:57
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
26.01.26 - 08:24
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, January 26, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
23.01.26 - 08:03
Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil (GlobeNewswire EN)
 
Bavarian Nordic has signed a distribution agreement with Eurofarma for its chikungunya vaccine in Brazil with potential to expand to rest of Latin America...
19.01.26 - 08:39
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, January 19, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
12.01.26 - 13:21
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, January 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....
07.01.26 - 08:12
Bavarian Nordic Launches Planned Share Buy-Back Program (GlobeNewswire EN)
 
COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026....
18.12.25 - 20:45
Bavarian Nordic Establishes Long-term Incentive Program for Members of Executive Management and Selected Employees (GlobeNewswire EN)
 
COPENHAGEN, Denmark, December 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management as part of the annual remuneration as laid out in the Remuneration Policy, adopted at the annual general meeting. Members of the Executive Management are granted performance restricted stock units (Performance RSUs), subject to the successful achievement of relevant Key Performance Indicators (KPI's), measured over a three-year performance period from grant. Furthermore, and also in accordance with the Remuneration Policy, a warrant program has been established for selected other employees in the Bavarian Nordic Group, entitling the warrant holders to subscribe for new shares in the Company, subject to certain terms, including a three-year vesting period....
17.12.25 - 08:33
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic (GlobeNewswire EN)
 
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic...
11.12.25 - 16:18
Bavarian Nordic Eyes Debt, Equity Funding After Failed Takeover (Bloomberg)
 
Bavarian Nordic A/S may use debt financing and tap equity markets to fund its growth plans after a take-private deal for the Danish vaccine maker fell through, according to its chief executive officer....
10.12.25 - 19:36
Bavarian Nordic: Reise ins Ungewisse (Der Aktionaer)
 
Das Portfolio von Bavarian Nordic ist begehrt. Ein Übernahmeversuch fand in diesem Jahr allerdings nicht genügend Zustimmung bei den Aktionären. Wie geht es nun weiter?...
02.12.25 - 08:03
Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million (GlobeNewswire EN)
 
Bavarian Nordic intends to launch a one-time share buy-back program of up to DKK 500 million...
26.11.25 - 21:03
Bavarian Nordic to Host a Shareholder Information Meeting on December 11, 2025 in Copenhagen (GlobeNewswire EN)
 
Bavarian Nordic invites shareholders to an information meeting with board and management on Dec 11, 09:00–10:30 CET in Copenhagen. Register by Dec 9....
15.11.25 - 09:30
Bavarian Nordic-Aktie: Der Wurm ist drin (Sharedeals)
 
Die Bavaria Nordic-Aktie durchlebt aktuell schwere Zeiten. Nachdem der Kurs des dänisch-deutschen Pharmaunternehmens bereits Ende letzter Woche um über -20% eingebrochen war, ging es auch am gestrigen Freitag um weitere -5% bergab. Was steckt hinter dem massiven Kurseinbruch und sollten Anleger jetzt zugreifen? Gescheiterte Übernahme Für den starken Kursrückgang der Bavarian Nordic-Aktie gibt es gleich […] The post Bavarian Nordic-Aktie: Der Wurm ist drin first appeared on sharedeals.de....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Eine schöne Frau gehört der Welt, eine häßliche dir allein. - Sprichwort Indien
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!